Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Heart Test Laboratories, Inc. ( (HSCS) ) has shared an announcement.
Heart Test Laboratories, Inc. announced that on September 26, 2025, it entered into Amendment No. 7 to its Loan Agreement with Front Range Ventures LLC, extending the maturity date of its promissory note to September 30, 2026. The company also disclosed a Regulation A Offering, which as of October 1, 2025, has generated $6.7 million in gross proceeds, resulting in the issuance of 1,912,383 units. Additionally, a debt exchange was conducted, reducing the principal and accrued interest by exchanging $2,060,000 in principal and $45,000 in accrued interest for shares of common stock.
The most recent analyst rating on (HSCS) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Heart Test Laboratories, Inc. stock, see the HSCS Stock Forecast page.
Spark’s Take on HSCS Stock
According to Spark, TipRanks’ AI Analyst, HSCS is a Neutral.
Heart Test Laboratories, Inc. is struggling with significant financial challenges, as reflected in its low financial performance score. The technical analysis provides some neutral signals, but the valuation remains poor due to negative earnings. The absence of earnings call data and corporate events limits further insights.
To see Spark’s full report on HSCS stock, click here.
More about Heart Test Laboratories, Inc.
Average Trading Volume: 132,597
Technical Sentiment Signal: Strong Sell
Current Market Cap: $9.06M
Find detailed analytics on HSCS stock on TipRanks’ Stock Analysis page.